Salud financiera de hoja de balance de Race Oncology

Salud financiera controles de criterios 6/6

Race Oncology tiene un patrimonio de los accionistas total de A$18.3M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$20.2M y A$1.9M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$17.19m
Patrimonio	AU$18.31m
Total pasivo	AU$1.92m
Activos totales	AU$20.23m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Recent updates

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$17.4M) de RAC superan a sus pasivos a corto plazo (A$1.9M).

Pasivo a largo plazo: Los activos a corto plazo de RAC (A$17.4M) superan a sus pasivos a largo plazo (A$48.3K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RAC está libre de deudas.

Reducción de la deuda: RAC no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RAC tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: RAC dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 29.3% cada año.

Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2024/12/20 07:30
Precio de las acciones al final del día	2024/12/20 00:00
Beneficios	2024/06/30
Ingresos anuales	2024/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Race Oncology Limited está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
null null	Independent Investment Research (Aust.) Pty Ltd
Chris Kallos	MST Financial Services Pty Limited

Salud financiera de hoja de balance de Race Oncology

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Recent updates

Race Oncology Limited, Annual General Meeting, Nov 25, 2024

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

New 90-day high: AU$3.29

Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results

Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited